Platelet Glycoprotein IIb/IIIa Receptor Inhibitors in Coronary Artery Disease
Authors: Marc Cohen
Journal: Annals of Internal Medicine (1996)

Editorials1 May 1996Platelet Glycoprotein IIb/IIIa Receptor Inhibitors in Coronary Artery DiseaseMarc Cohen, MDMarc Cohen, MDMedical College of Pennsylvania and Hahnemann University School of Medicine Philadelphia, PA 19102-1192Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-9-199605010-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Drugs that dissolve blood clots (thrombolytic agents) and drugs that prevent clot propagation (antiplatelet agents and anticoagulant agents) are used to treat a broad array of cardiovascular diseases. Platelets are a key component of all blood clots propagating within the arterial circulation and thus are an obvious therapeutic target in attempts to inhibit coronary artery thrombosis. However, despite evidence that clearly documents the beneficial effects of aspirin over placebo in acute coronary syndromes, many patients still “break through” aspirin [1, 2]. Ticlopidine, commonly used with aspirin in patients with intracoronary stents [3], has a beneficial profile similar to that of ...References1. Cohen M, Parry G, Adams PC, Xiong J, Chamberlain D, Wieczorek I, et al. Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Eur Heart J. 1994; 15:1196-203. Google Scholar2. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol. 1995; 11:221-7. Google Scholar3. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation. 1996; 93:215-22. Google Scholar4. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 1990; 82:17-26. Google Scholar5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC investigation. N Engl J Med. 1994; 330:956-61. Google Scholar6. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thombasthenic-like state in normal platelets and binds to glycoprotein IIb and/or IIIa. J Clin Invest. 1983; 72:325-38. Google Scholar7. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, et al. Randomized trial of GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation. 1994; 89:596-603. Google Scholar8. Horrigan MC, Tcheng JE, Califf RM, Kitt M, Lorenz T, Sigmon K, et al. Maximal benefit of integrelin platelet IIb/IIIa blockade 6-24 hours after therapy: results of the IMPACT-II trial [Abstract]. J Am Coll Cardiol. 1996; 27(Suppl A):55A. Google Scholar9. Kereiakes DJ, Kleiman NS, Ambrose JA, Cohen M, Rodriguez S, Palabrica T, et al. A randomized, double blind, placebo controlled dose ranging study of Tirofiban (MK-383) platelet IIb/IIIa receptor blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996; 27:536-42. Google Scholar10. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction in clinical restenosis: results at six months. The EPIC Investigators. Lancet. 1994; 343:881-6. Google Scholar11. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin αV β3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 1995; 96:1815-22. Google Scholar12. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994; 90:2203-6. Google Scholar13. Simpfendorfer C, Kottke-Marchant K, Topol EJ. First experience with chronic platelet GPIIb/IIIa receptor blockade. A pilot study of Xemlofiban an orally active antagonist in unstable angina patients eligible for PTCA [Abstract]. J Am Coll Cardiol. 1996; 27(Suppl A):242A. Google Scholar Author, Article, and Disclosure InformationAffiliations: Medical College of Pennsylvania and Hahnemann University School of Medicine Philadelphia, PA 19102-1192Corresponding Author: Marc Cohen, MD, Cardiac Catheterization Laboratory, Mail Stop 119, Hahnemann University Hospital, Philadelphia, PA 19102-1192. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByVITPOR AI, A Coagulation Factor XIIa Inhibitor from Porphyra yezoensis: In Vivo Mode of Action and Assessment of Platelet Function AnalysisA novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregationTherapeutics of Platelet Glycoprotein IIb/IIIa Receptor AntagonismBleeding and hemostatic defects in uremiaEffect of Glycoprotein IIb/IIIa Antagonists on the HIT Serum Induced Activation of PlateletsAcetylsalicylsäure im Vergleich zu anderen Thrombozytenfunktionshemmern — Wirkungsmechanismen 1 May 1996Volume 124, Issue 9Page: 843-844KeywordsAnticoagulantsAspirinDrugsGlycoproteinsIntegrinsMonoclonal antibodiesPlatelet aggregationPlateletsStable coronary artery diseaseThrombosis Issue Published: 1 May 1996 CopyrightCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...